JP7811908B2 - がんを治療するためのソルチリン結合コンジュゲート化合物、組成物、およびそれらの使用 - Google Patents

がんを治療するためのソルチリン結合コンジュゲート化合物、組成物、およびそれらの使用

Info

Publication number
JP7811908B2
JP7811908B2 JP2022534215A JP2022534215A JP7811908B2 JP 7811908 B2 JP7811908 B2 JP 7811908B2 JP 2022534215 A JP2022534215 A JP 2022534215A JP 2022534215 A JP2022534215 A JP 2022534215A JP 7811908 B2 JP7811908 B2 JP 7811908B2
Authority
JP
Japan
Prior art keywords
cancer
composition
compound
formula
peptide compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022534215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505298A5 (https=
JP2023505298A (ja
Inventor
クリスチャン マルソレ
ミシェル ドゥムル
ジャン クリストフ キュリー
アラン ラロック
Original Assignee
ゼラテクノロジーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼラテクノロジーズ インコーポレイテッド filed Critical ゼラテクノロジーズ インコーポレイテッド
Publication of JP2023505298A publication Critical patent/JP2023505298A/ja
Publication of JP2023505298A5 publication Critical patent/JP2023505298A5/ja
Application granted granted Critical
Publication of JP7811908B2 publication Critical patent/JP7811908B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022534215A 2019-12-06 2020-12-07 がんを治療するためのソルチリン結合コンジュゲート化合物、組成物、およびそれらの使用 Active JP7811908B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945111P 2019-12-06 2019-12-06
US62/945,111 2019-12-06
PCT/CA2020/051686 WO2021108929A1 (en) 2019-12-06 2020-12-07 Sortilin binding conjugate compounds, compositions and uses thereof for treating cancer

Publications (3)

Publication Number Publication Date
JP2023505298A JP2023505298A (ja) 2023-02-08
JP2023505298A5 JP2023505298A5 (https=) 2023-12-04
JP7811908B2 true JP7811908B2 (ja) 2026-02-06

Family

ID=76220889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534215A Active JP7811908B2 (ja) 2019-12-06 2020-12-07 がんを治療するためのソルチリン結合コンジュゲート化合物、組成物、およびそれらの使用

Country Status (9)

Country Link
US (1) US20230036041A1 (https=)
EP (1) EP4069309A4 (https=)
JP (1) JP7811908B2 (https=)
KR (1) KR20220113980A (https=)
CN (1) CN114980932B (https=)
AU (1) AU2020395148A1 (https=)
CA (1) CA3160722A1 (https=)
IL (1) IL293553A (https=)
WO (1) WO2021108929A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116731113A (zh) * 2022-03-01 2023-09-12 上海智肽生物科技有限公司 针对sort1的多肽化合物及其药物偶联物
CN120641133A (zh) * 2022-11-14 2025-09-12 瑟瑞技术公司 用于刺激抗肿瘤免疫应答的药物缀合物化合物
CN118384289A (zh) * 2024-04-24 2024-07-26 青岛科技大学 一种肿瘤靶向肽及多肽偶联药物的制备方法及应用
WO2025236098A1 (en) * 2024-05-16 2025-11-20 Theratechnologies Inc. Peptide conjugates of maytansinoids and uses thereof
WO2026021513A1 (zh) * 2024-07-25 2026-01-29 上海湃鸿生物科技有限公司 一种多肽药物偶联物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504361A (ja) 2006-09-25 2010-02-12 メディミューン，エルエルシー 安定した抗体製剤およびその使用
JP2019501141A (ja) 2015-11-24 2019-01-17 トランスフェール プリュ エス．ウ．セ． 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525033A (ja) * 2004-12-22 2008-07-17 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｂ群連鎖球菌
US8147849B2 (en) * 2009-02-20 2012-04-03 Novartis Ag Protective antigens for group B Streptococcus hypervirulent strains
KR101074936B1 (ko) * 2009-05-25 2011-10-18 보령제약 주식회사 도세탁셀 주사제용 조성물 및 그의 제조방법
CN101708177B (zh) * 2009-11-23 2012-09-05 浙江万马药业有限公司 一种含多西他赛的药物组合物及其制备方法
JP6285725B2 (ja) * 2014-01-16 2018-02-28 ナガセ医薬品株式会社 エタノールフリードセタキセル医薬組成物
SMT202500367T1 (it) * 2017-02-02 2025-11-10 Amgen Res Munich Gmbh Composizione farmaceutica a basso ph comprendente costrutti di anticorpo che reclutano le cellule t
EP3625245A4 (en) * 2017-05-24 2020-12-16 Transfert Plus, S.E.C. PEPTIDIC COMPOUNDS, CONJUGATE COMPOUNDS AND THEIR USES IN THE TREATMENT OF INFLAMMATORY DISEASES
CN111465389B (zh) * 2017-09-07 2022-06-21 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504361A (ja) 2006-09-25 2010-02-12 メディミューン，エルエルシー 安定した抗体製剤およびその使用
JP2019501141A (ja) 2015-11-24 2019-01-17 トランスフェール プリュ エス．ウ．セ． 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Adv Ther，2018年，Vol.35，pp.754-767
Ann Allergy Asthma Immunol，2005年，Vol.95，pp.593-599

Also Published As

Publication number Publication date
JP2023505298A (ja) 2023-02-08
AU2020395148A1 (en) 2022-06-23
EP4069309A1 (en) 2022-10-12
WO2021108929A1 (en) 2021-06-10
IL293553A (en) 2022-08-01
EP4069309A4 (en) 2024-03-27
US20230036041A1 (en) 2023-02-02
CN114980932B (zh) 2026-01-02
CA3160722A1 (en) 2021-06-10
CN114980932A (zh) 2022-08-30
KR20220113980A (ko) 2022-08-17

Similar Documents

Publication Publication Date Title
JP7811908B2 (ja) がんを治療するためのソルチリン結合コンジュゲート化合物、組成物、およびそれらの使用
CA3071494C (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
JP7592320B2 (ja) ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物
US20170326233A1 (en) Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
EP2509421B1 (en) Drug delivery of temozolomide for systemic based treatment of cancer
KR20180090290A (ko) 사차화 튜불리신 화합물들의 컨쥬게이트들
US20160106856A1 (en) Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
BR112019024563A2 (pt) Compostos peptídicos, compostos conjugados e usos dos mesmos para tratar doenças inflamatórias
TW202515620A (zh) 抗體－藥物偶聯物靶向治療前列腺癌和其他腫瘤
KR20220012278A (ko) 약물 컨쥬게이트 및 이의 사용 방법
JP2023548310A (ja) Ｆａｐ活性化血清半減期延長型治療用コンジュゲート
US20230346969A1 (en) Intermediate for preparing antibody-drug conjugate (adc), preparation method therefor, and use thereof
CN109982720A (zh) 抗体药物缀合物
JP2025090582A (ja) がん治療のためのペプチド誘導体とそのコンジュゲート
CN119868576A (zh) 用于制备抗体与药物偶联物的中间体及其制备方法和应用
Chen et al. Degrader-Drug Conjugate (DDC) Mediated Immunochemotherapy for Tumor Treatment
TW202525345A (zh) 抗psma adc接合物組成物及其使用方法
HK40066016A (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
HK40066016B (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
JP2025541984A (ja) 抗腫瘍免疫応答を刺激するための薬物結合体化合物
BR112018010535B1 (pt) Compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor
HK1259948A1 (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251022

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260127

R150 Certificate of patent or registration of utility model

Ref document number: 7811908

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150